Case Editor - Jeremy Falk
Reviewed By Clinical Problems Assembly
Submitted by
Parag B. Desai, MD
Fellow
Pulmonary and Critical Care Medicine
Temple University School of Medicine
Philadelphia, Pennsylvania
Jason Krahnke, DO
Internal Medicine Resident
Temple University School of Medicine
Philadelphia, Pennsylvania
A. James Mamary, MD
Assistant Professor of Medicine
Temple University School of Medicine
Philadelphia, Pennsylvania
Submit your comments to the author(s).
History
The patient is a 24-year-old Asian-Indian male who initially presented to a community hospital with a 10-day history of mild hemoptysis (2 -3 tablespoons of blood per day), followed by arthralgias, joint stiffness (knees, shoulders, elbows) and myalgias of the proximal muscles. Moreover, he complained of tactile fevers but denied any rashes. He also complained of a slight occipital headache, pleuritic chest pain (right greater than left), and loose watery diarrhea without hematochezia or melena. An initial chest radiograph showed a left upper lobe infiltrate and hilar adenopathy. The patient was treated for community-acquired pneumonia with Levofloxacin, Ceftriaxone and Azithromycin. He then developed hypoxic respiratory failure requiring 100% oxygen via a non-rebreather mask. A computed tomography of the chest showed diffuse patchy, ill-defined infiltrates and increased interstitial markings at the bases. There was no evidence of pulmonary embolism. He was transferred to a tertiary care hospital.
His past medical history was significant for exercise-induced asthma, diagnosed 1 year prior to presentation. He infrequently used a short-acting β2-agonist. He was also diagnosed with ulcerative colitis 2 years prior. He presented with a single bloody stool, after which he had several colonic biopsies. Initially, these were thought to be diagnostic of ulcerative colitis. On retrospective review at the tertiary care center, the biopsies showed diffuse eosinophilic infiltration and inflammation, and were not consistent with a diagnosis of ulcerative colitis. He tested positive for c-ANCA antibody in 2006. He was treated for minimal change disease in childhood.
He denied tobacco, alcohol or illicit drug use. He denied any recent travel. He did not have any pets.
Family history was unremarkable.
His current medications included mesalamine 1600 mg twice daily and a short-acting β2 -agonist as needed.
Physical Exam
(Upon arrival to the tertiary care center):
On physical examination he was afebrile with a temperature of 97.4 °F, tachycardic with a pulse 108 beats per minute, tachypneic with a respiratory rate of 24 breaths per minute. He was normotensive. He appeared to be in mild respiratory distress but was awake, alert and appropriate. He had no oral ulcers. There was no central cyanosis. There was no palpable cervical, supraclavicular or axillary lymphadenopathy. On pulmonary examination he had dense expiratory wheezing diffusely. There was no stridor. Cardiac examination revealed tachycardia but no murmurs, rubs or gallops. Abdomen was soft with presence of bowel sounds. There was no hepatosplenomegaly. His joints were non-tender, not warm to touch and free of swelling or deformity. He had a purplish, flat, macular rash on his palms. The extremities were free of clubbing, cyanosis or edema.
Significant labs/tests from the community hospital:
White blood cell count 19,800/mm3, Hemoglobin 15.2 g/dl, Platelet count 175,000/mm3
Differential significant for 35% eosinophils
Creatinine 1.4 mg/dl, cardiac troponin 2.2 ng/ml, creatinine kinase 860 U/L, AST 214 U/L, ALT 81 U/L, Total bilirubin 0.7 mg/dl, INR 1.38 seconds
ESR 14 mm/hr, CRP 11.7 mg/dl
Urinalysis significant for 3+ amorphous sediment, 1+ protein, no blood
EKG showed sinus tachycardia with a right bundle branch block
Testing at tertiary care hospital:
Lab
White blood cell count 23,200/mm3, Hemoglobin 16.8 g/dl, Platelet count 214,000/mm3
Differential: 86% segmented neutrophils, 7% lymphocytes, and 5% eosinophils
Creatinine 1.1 mg/dl, cardiac troponin 18.2 ng/ml, creatinine kinase 526 U/L, AST 88 U/L, ALT 61 U/L, INR 1.2 seconds
ESR 15 mm/hr, CRP 13 mg/dl
ANA, SS-A, SS-B, c-ANCA, p-ANCA, Scl-70, ds DNA, glomerular base membrane, sm/RNP antibodies all negative
RF was mildly elevated at 49 IU/ml
C3, C4, CH50 complement levels within normal limits
Mycoplasma IgG antibody was equivocal
Legionella urinary antigen negative
IgE 2140 IU/mL (elevated)
IgG within normal limits
TSH within normal limits
Hepatitis panel negative
HIV-1/2 antibody negative
Studies:
Echocardiogram: dilated left ventricle with left ventricular ejection fraction of 20%; moderate to markedly increased wall thickness with a speckling pattern; mild to moderate mitral regurgitation; dilated left atrium; dilated right ventricle with estimated systolic pressure of 45mmHg; small pericardial effusion.
Venous duplex ultrasound of bilateral upper and lower extremities was negative for deep vein thrombosis.
Figures

Figure 1: Admission posterior-anterior (PA) chest radiograph showing bibasilar patchy opacities with obscured diaphragms and an enlarged cardiac silhouette suggesting cardiomegaly.

Figure 2: CT Sinus: showing opacified left inferior maxillary sinus.
The Churg-Strauss syndrome (CSS), also called allergic granulomatosis and angiitis, is a multisystem disorder characterized by allergic rhinitis, asthma, and prominent peripheral blood eosinophilia or tissue eosinophilia (1). In 1951, Churg and Strauss first described the syndrome in 13 patients who had asthma, eosinophilia, granulomatous inflammation, necrotizing systemic vasculitis and necrotizing glomerulonephritiS (2). CSS is classified as a vasculitis of the small- and medium-sized arteries and veins. It is the least common of the three anti-neutrophil cytoplasmic antibody (ACNA)-associated vasculitides (the others being Wegener’s granulamatosis and microscopic polyangiitis). Pulmonary involvement, primarily asthma, is present in all cases. On presentation, patients often have pulmonary infiltrates on chest radiograph (30-70% of cases), but they may also have sinusitis, neuropathy, constitutional symptoms, or gastrointestinal or cardiac manifestations (1). Although the eosinophil is believed to play a central role in the pathogenesis of CSS, the etiology of this syndrome remains unknown and is likely a combination of heightened T-cell immunity and altered humoral immunity, and represents an autoimmune process. CSS may occur in patients of any age, but it develops most commonly in patients between the ages of 38 to 50. There is no clear gender predominance (3). CSS has three phases: the prodromal phase occurs in the second to third decades of life and is characterized by atopic disease, allergic rhinitis and asthma; the eosinophilic phase is typified by development of marked peripheral blood eosinophilia and eosinophilic tissue infiltration, most commonly of the lung, gastrointestinal tract and skin. The vasculitic phase is characterized by vasculitis of the small and medium vessels with vascular and extravascular granulomas and is often heralded by development of constitutional symptoms. Typically the vasculitic phase occurs several years after the onset of asthma, but it can develop within months of, or concomitant with, the onset of asthma. A short duration between the onset of asthma and vasculitis is associated with increased severity of vasculitis (1). The most prominent symptoms and signs are those related to pulmonary, cardiac, dermatologic, renal and peripheral nerve involvement. Mononeuritis multiplex is a major clinical finding.
The following list includes the symptoms and signs of the disease as reported by Guillevin et al (1999) in their case series (4):
- Constitutional - Malaise, fatigue, flulike symptoms, weight loss (70%), fever (57%), myalgias (52%)
- Asthma-like syndrome - Asthma is a central feature of CSS, occurring in 97% of patients. Asthma may precede vasculitis by up to 10 years or, less frequently, may coincide with the appearance of vasculitis.
- Paranasal sinusitis (61%)
- Allergic rhinitis
- Other pulmonary (37%) - cough and hemoptysis
- Rheumatologic - arthralgias (40%)
- Dermatologic (49%) - Purpura, skin nodules, urticarial rash, necrotic bullae, digital ischemia
- Cardiac - Symptoms related to heart failure, myocarditis, pericarditis, constrictive pericarditis and myocardial infarction
- Gastrointestinal (31%) - Symptoms related to gastrointestinal vasculitis, eosinophilic gastritis, colitis, including abdominal pain [59%], diarrhea [33%] and gastrointestinal bleeding [18%].)
- Neurologic - Mononeuritis multiplex (most frequent form, occurring in as many as 77% of patients)
- Renal - about 25% with CSS have acute renal insufficiency or rapidly progressive disease
- Other - Symptoms related to stroke or ophthalmologic involvement
Allergic bronchopulmonary aspergillosis is another cause of asthma, radiographic pulmonary opacities and eosinophilia, but does not affect extrapulmonary organs other than the nose and the sinuses (5).
Asthma is not a prominent feature the hypereosinophilic syndrome and very few patients with hypereosinophilic syndrome have pulmonary infiltrates (5).
Chronic eosinophilic pneumonia generally does not involve organs other than the lungs (6).
The degree of eosinophilia seen in CSS along with the presence of asthma are usually not seen in Wegener’s granulmatosis (6).
The six criteria for the classification of CSS as established by the American College of Rheumatology include the following (7):
- Asthma (a history of wheezing or the finding of diffuse high pitched wheezing)
- Greater than 10% eosinophils on the differential leukocyte count
- Mononeuropathy (including mononeuritis multiplex) and polyneuropathy
- Migratory or transient pulmonary opacities
- Paranasal sinus disease
- Biopsy containing a blood vessel with accumulation of eosinophils in an extravascular compartment
The presence of four or more of these has a sensitivity of 85% and specificity of 99.7%.
Of note, the Lanham criteria include asthma, peak peripheral blood eosinophilia in excess of 1500 cells/µl, and systemic vasculitis involving two or more extra-pulmonary organs; in this classification system, all three criteria must be met (8).
50% of patients with untreated CSS die within 3 months. The “five-factor score” (FFS) is used to assess disease severity and guide therapy. It is based on the presence or absence of the following clinical factors: cardiac involvement, gastrointestinal disease (bleeding, perforation, infarction or pancreatitis), renal insufficiency (plasma creatinine concentration > 1.6 mg/dl), proteinuria (>1 g/day) and central nervous system involvement. The presence of each factor is given one point (9). The primary therapy for CSS is glucocorticoids. Prednisone doses of 0.5 to 1.5 mg/kg are administered for 6 – 12 weeks or until disease remission is attained and then gradually tapered (10). Cyclophosphamide should be added to glucocorticoids for a FFS of 2 or FFS 1 when there is cardiac or central nervous system involvement. Transition to azathioprine is recommended after induction of remission with cyclophosphamide to sustain remission (11, 12).
Methotrexate can be used as an alternative steroid sparing agent, however one should be mindful of the development of methotrexate pneumonitis, which can be difficult to differentiate from the original disease process.9 Patients with severe disease treated with corticosteroids and cyclophosphamide have better survival than those treated with corticosteroids alone (12).
Most deaths in CSS result from complications during the vasculitic phase of the disease. All of the above are the most common reasons for death. Survival in CSS is predicted using the “five-factor score” (FFS). The FFS is based on the presence or absence of the following clinical factors: cardiac involvement; gastrointestinal disease (bleeding, perforation, infarction or pancreatitis); renal insufficiency (plasma creatinine concentration > 1.6 mg/dl); proteinuria (>1 g/day); central nervous system involvement. The presence of each factor is given one point. A large series reported the following 5-year mortality figures based on the FFS: 12% when none of the five prognostic factors are present; 26% when one factor was present; 46% when three or more factors were present. Of the five factors, cardiac involvement and gastrointestinal disease appear to be the strongest indicators of poor prognosis (4, 13).
CSS has been reported as a rare complication in patients with systemic glucocorticoid-dependent asthma who were treated with a leukotriene modifying agent, but usually in the setting of reduction in dose of oral glucocorticoids. The LTMA may unmask CSS by facilitating glucocorticoid withdrawal or patients who have undiagnosed CSS are prescribed a LTMA because of worsening symptoms and the LTMA is insufficient to control CSS (14).
Also, the onset of CSS has also occurred when the addition or increase in inhaled glucocorticoids allowed reduction in the dose of systemic glucocorticoids, helping to “unmask” CSS symptoms (15).
Similarly, in patients with severe asthma receiving omalizumab, the appearance of CSS preceded treatment with omalizumab or coincided with tapering of systemic steroids, suggesting that omalizumab was added in setting of worsening CSS or that it allowed the “unmasking” of underlying CSS (16).
Free-base cocaine has been associated with an unusual CSS-like vasculitis. The ANCAs recognize human neutrophil elastase as the target antigen whereas the ANCAs from CSS react to myeloperoxidase (17).
Summary:
This 24-year-old man likely presented in the vasculitic phase of Churg-Strauss syndrome manifested by likely diffuse alveolar hemorrhage, rash and myocarditis with concomitant asthma exacerbation. He was started on pulse dose steroids with significant improvement in oxygenation. He was on room air within 48 hours of arrival and thereafter was started on cyclophosphamide, with improved left ventricular function and decreased IgE levels.
Figure 3: PA chest radiograph after treatment showing resolving bibasilar opacities and pulmonary interstitial edema, enlarged cardiac silhouette remains.

References
- Crothers K, Rochester C. The Eosinophilic Pneumonias. Fishman’s Pulmonary Disease and Disorders, 4th ed. New York: McGraw Hill, 2008.
- Churg J, Strauss L. Allergic granulamatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951:27:277.
- Keogh KA, Specks U. Churg-Strauss Syndrome. Semin Respir Crit Care Med 2006;27:148.
- Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow up of 96 patients. Medicine (Baltimore) 1999;78:26.
- Allen JN, Davis WB. Eosinophilic lung diseases. Am J Resp Crit Care Med 1994;150;1423.
- King Jr, T. Clinical features and diagnosis of Churg-Strauss syndrome. UpToDate 2010.
- Masi A, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome. Arthritis Rheum 1990;33:1094.
- Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophillia: A clinical approach to the Churg-Strauss syndrome. Medicine 1984;63:65.
- Guellvin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churgh-Strauss syndrome. A prospective study in 342 patients. Medicine 1996;75:17.
- King Jr. Treatment and prognosis of Churg-Strauss syndrome. UpToDate 2010.
- Sinico RA, Bottero P. Churg-Strauss Angiitis. Best Pract Res Clin Rheumatol 2009;23:355.
- Pagnoux, C, Guilpain P, Guellvin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007;19:25.
- Keogh KA, Speck U. Churg-Strauss syndrome. Clinical presentation, antineutrophil cytoplasmic antibodies and leukotriene receptor antagonists. Am J Med 2003;115:284.
- Keogh KA. Leukotriene receptor antagonists and Churg-Strauss syndrome: cause, trigger or merely an association? Drug Saf 2007;30:837.
- Cooper SM, Libman BS, Lazarovich M. Churg-Strauss syndrome in a group of patients receiving fluticasone for asthma. J Rheumatol 2002;29;2651.
- Wechsler ME, Wong DA, Miller MK, et al. Churgh-Strauss syndrome in patients treated with omalizumab. Chest 2009;136:507.
- Orriols R, Munoz X, Ferrer J, et al. Cocaine-induced Churg-Strauss vasculitis. Eur Respir J 1996;9:175.